Developer docs
API playgroundTry for free, no card

Search company profiles

FORUS Therapeutics

Full company profile

uuid02imaro

Namestring
FORUS Therapeutics
Legal namestring
FORUS Therapeutics Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

FORUS Therapeutics is a Canadian specialty biopharmaceutical company founded in January 2021 and headquartered in Oakville, Ontario. The company commercializes two hematology/oncology assets in Canada: BESREMI (ropeginterferon alfa-2b), a long-acting interferon approved by Health Canada in July 2026 for polycythemia vera (a rare myeloproliferative blood cancer), and XPOVIO (selinexor), a first-in-class oral selective inhibitor of nuclear export (SINE) compound indicated for multiple myeloma. FORUS operates as a wholly-owned subsidiary of PharmaEssentia Corporation following its June 2026 acquisition.

The company's business model centers on in-licensing late-stage or approved oncology assets from global developers — Karyopharm (XPOVIO, January 2021) and PharmaEssentia (BESREMI, October 2024) — and commercializing them exclusively in Canada through the pan-Canadian Pharmaceutical Alliance (pCPA) and provincial drug reimbursement frameworks. Revenue is generated through specialty drug distribution to hematology clinics and oncology centers treating patients with polycythemia vera and relapsed/refractory multiple myeloma. The go-to-market relies on securing provincial formulary listings and reimbursement, with XPOVIO completing pan-Canadian public coverage in November 2025 and BESREMI newly approved in mid-2026.

FORUS is led by CEO Kevin Leshuk, whose prior senior roles at Pfizer, Roche Canada, and Celgene anchor the company's specialty oncology commercialization expertise. The company was initially capitalized with approximately $20M CAD in equity and $2.5M CAD in debt, and its current corporate trajectory is shaped by the PharmaEssentia acquisition, which provides the balance sheet and corporate infrastructure for scaling the Canadian commercial franchise.

Short descriptiontext

FORUS Therapeutics is a Canadian specialty biopharmaceutical company that in-licenses and commercializes approved hematology/oncology drugs — BESREMI for polycythemia vera and XPOVIO for multiple myeloma — exclusively in Canada through provincial drug plans, serving patients with rare blood cancers and myeloma.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOakville, Canada
HQ citystring
Oakville
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
hematology oncology drugs, specialty pharmaceuticals, cancer therapeutics, polycythemia vera treatment, multiple myeloma therapy
Industry3 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals - Oncology/Hematology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

FORUS generates revenue through the sale of prescription pharmaceutical products (BESREMI and XPOVIO) to healthcare providers, hospitals, and through public/private drug plan reimbursement across Canadian provinces.

forustherapeutics.com
2Licensing Revenue
TypeLicensing Royalties
Description

As a wholly owned subsidiary of PharmaEssentia Corp following acquisition in June 2026, FORUS operates under licensing agreements with PharmaEssentia (BESREMI) and Karyopharm Therapeutics (XPOVIO) for Canadian commercialization rights.

forustherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

FORUS Therapeutics commercializes two specialty prescription pharmaceutical products in Canada: BESREMI® (ropeginterferon alfa-2b), a long-acting interferon injection for adults with polycythemia vera, and XPOVIO® (selinexor), an oral XPO1 inhibitor for adults with multiple myeloma. Both drugs are in-licensed from PharmaEssentia and Karyopharm Therapeutics, and FORUS handles Canadian regulatory approvals, market access negotiations with provincial drug plans, medical affairs, and field-based sales to hematologists and oncologists.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • XPOVIO achieved public funding across multiple provinces including Alberta, Saskatchewan, British Columbia, Ontario, Newfoundland and Labrador, New Brunswick, Nova Scotia, PEI, and Quebec
+2 more records
Product overview1 text field

FORUS Therapeutics is a Canadian specialty pharmaceutical company that commercializes differentiated medicines for hematologic malignancies and cancer. The company operates with two core commercialized products: BESREMI® (ropeginterferon alfa-2b), a long-acting interferon for polycythemia vera obtained through licensing from parent company PharmaEssentia; and XPOVIO® (selinexor), an XPO1 inhibitor for multiple myeloma licensed from Karyopharm Therapeutics. Both products target rare hematologic cancers and are supported by patient assistance programs and market access initiatives across Canadian provinces.

Product and service3 records
1BESREMI® (ropeginterferon alfa-2b)
CategorySpecialty Pharmaceutical - Oncology/Hematology
Description

A monopegylated, long-acting interferon alfa-2b injection for the treatment of adults with polycythemia vera (PV), a rare chronic blood cancer. Administered subcutaneously once every two weeks (or every four weeks with hematological stability). Licensed from PharmaEssentia Corp.

2XPOVIO® (selinexor)
CategorySpecialty Pharmaceutical - Oncology/Hematology
Description

A first-in-class oral selective nuclear export (XPO1) inhibitor (SINE) in tablet form, indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Licensed from Karyopharm Therapeutics Inc.

3ForYOU Patient Support Program (PSP)
CategoryPatient Support Services
Description

A dedicated patient support service for Canadian patients prescribed FORUS products (notably XPOVIO), assisting with reimbursement navigation, financial assistance, and treatment adherence via phone (1-833-496-8777) and fax.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-11
Description

PharmaEssentia acquired FORUS Therapeutics in June 2026, making it a wholly owned subsidiary. FORUS continues to leverage its established expertise in the Canadian hematology and oncology environment while benefiting from expanded global resources and capabilities. The acquisition strengthens the combined organization's ability to support regulatory, medical, market access, and commercial activities across Canada. FORUS previously held exclusive licensing rights for BESREMI (ropeginterferon alfa-2b) for polycythemia vera in Canada.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Bloom Burton & Co. is a healthcare investor conference organizer. FORUS has presented at multiple Bloom Burton & Co. Healthcare Investor Conferences (2022, 2023) as part of their investor relations and corporate visibility strategy.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

FORUS participates in the Pharmaceutical & Healthcare Management and Innovation (PHMI) graduate program at Queen's University, hosting interns through the program as part of talent development and academic engagement.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Patient advocacy organization representing myeloproliferative neoplasm (MPN) patients in Canada. Doug Chisholm (former Chair) and Patricia Saluk (current President) have publicly supported BESREMI availability in Canada.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian specialty pharmaceutical company now operating as a subsidiary of Endo, specializing in in-licensing, acquiring, and commercializing specialty products in Canada. Strong overlap in business model and Canadian commercialization expertise.

TypeDirect peer
Description

Canadian specialty pharmaceutical company focused on women's health and oncology, in-licensing and commercializing products in Canada. Similar in-licensing model and Canadian-only commercial focus, with a relevant oncology overlap.

TypeDirect peer
Description

Canadian specialty pharmaceutical company based in Mississauga that acquires, in-licenses, and commercializes specialty products in Canada. Similar business model of bringing differentiated, often niche, therapies to the Canadian market through licensing partnerships.

TypeDirect peer
Description

Canadian specialty pharmaceutical company commercializing cardiovascular therapies, including an FDA-approved product. While therapeutic focus differs, the model of a Canadian-domiciled specialty pharma commercializing novel, differentiated therapies is directly comparable.

5Bristol Myers Squibb Canada
TypeBroad incumbent
Description

Canadian operations of BMS, the parent of former Celgene and a leader in multiple myeloma (Revlimid, Pomalyst, Empliciti). Competes with XPOVIO in multiple myeloma and relevant because FORUS's leadership team largely hails from Celgene Canada.

TypeDirect peer
Description

Canadian specialty pharmaceutical company headquartered in Montreal that in-licenses and commercializes innovative products in Canada and select emerging markets. Closely comparable to FORUS in business model (in-licensed assets, Canadian commercialization focus) and oncology/hematology overlap.

TypeOthers
Description

Taiwan-based global biopharmaceutical company (TWSE: 6446) and FORUS's parent since June 2026; originator of BESREMI. Included as the strategic acquirer and primary licensor of FORUS's flagship asset.

TypeDirect peer
Description

Canadian specialty biopharmaceutical company focused on oncology and HIV, commercializing in-licensed and proprietary products. Comparable commercial-stage Canadian specialty pharma with a focus on serious conditions and narrow prescriber networks.

TypeOthers
Description

U.S.-based oncology company that developed XPOVIO (selinexor) and licensed Canadian commercialization rights to FORUS in 2021. Included as the originator of FORUS's other core product and a key licensor.

TypeBroad incumbent
Description

Canadian-headquartered specialty pharmaceutical company with a broad portfolio across dermatology, gastroenterology, and neurology. Operates at significantly larger scale than FORUS but shares the Canadian commercial infrastructure and specialty pharma model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

FORUS Therapeutics

Specialty Pharmaceuticals - Oncology/Hematologyforustherapeutics.com

FORUS Therapeutics is a Canadian specialty biopharmaceutical company that in-licenses and commercializes approved hematology/oncology drugs — BESREMI for polycythemia vera and XPOVIO for multiple myeloma — exclusively in Canada through provincial drug plans, serving patients with rare blood cancers and myeloma.

What FORUS Therapeutics does

FORUS Therapeutics is a Canadian specialty biopharmaceutical company founded in January 2021 and headquartered in Oakville, Ontario. The company commercializes two hematology/oncology assets in Canada: BESREMI (ropeginterferon alfa-2b), a long-acting interferon approved by Health Canada in July 2026 for polycythemia vera (a rare myeloproliferative blood cancer), and XPOVIO (selinexor), a first-in-class oral selective inhibitor of nuclear export (SINE) compound indicated for multiple myeloma. FORUS operates as a wholly-owned subsidiary of PharmaEssentia Corporation following its June 2026 acquisition.

The company's business model centers on in-licensing late-stage or approved oncology assets from global developers — Karyopharm (XPOVIO, January 2021) and PharmaEssentia (BESREMI, October 2024) — and commercializing them exclusively in Canada through the pan-Canadian Pharmaceutical Alliance (pCPA) and provincial drug reimbursement frameworks. Revenue is generated through specialty drug distribution to hematology clinics and oncology centers treating patients with polycythemia vera and relapsed/refractory multiple myeloma. The go-to-market relies on securing provincial formulary listings and reimbursement, with XPOVIO completing pan-Canadian public coverage in November 2025 and BESREMI newly approved in mid-2026.

FORUS is led by CEO Kevin Leshuk, whose prior senior roles at Pfizer, Roche Canada, and Celgene anchor the company's specialty oncology commercialization expertise. The company was initially capitalized with approximately $20M CAD in equity and $2.5M CAD in debt, and its current corporate trajectory is shaped by the PharmaEssentia acquisition, which provides the balance sheet and corporate infrastructure for scaling the Canadian commercial franchise.

FORUS Therapeutics firmographics

Firmographics
Name
FORUS Therapeutics
Legal name
FORUS Therapeutics Inc.
Website
https://forustherapeutics.com
Company type
Private
Founded year
2021
Operating status
Acquired
Headcount range
11–50 employees
Short description
FORUS Therapeutics is a Canadian specialty biopharmaceutical company that in-licenses and commercializes approved hematology/oncology drugs — BESREMI for polycythemia vera and XPOVIO for multiple myeloma — exclusively in Canada through provincial drug plans, serving patients with rare blood cancers and myeloma.
Ownership category
akta.pro rank

FORUS Therapeutics industry classification

Industry
Product category
Specialty Pharmaceuticals - Oncology/Hematology
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)

Keywords

  • Hematology oncology drugs
  • Specialty pharmaceuticals
  • Cancer therapeutics
  • Polycythemia vera treatment
  • Multiple myeloma therapy

Where FORUS Therapeutics is headquartered

Location

Headquarters

HQ city
Oakville
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

FORUS Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Marketing or Sales, Operations, Technology or R&D

Revenue model

  1. Pharmaceutical Product Sales: FORUS generates revenue through the sale of prescription pharmaceutical products (BESREMI and XPOVIO) to healthcare providers, hospitals, and through public/private drug plan reimbursement across Canadian provinces.
  2. Licensing Revenue: As a wholly owned subsidiary of PharmaEssentia Corp following acquisition in June 2026, FORUS operates under licensing agreements with PharmaEssentia (BESREMI) and Karyopharm Therapeutics (XPOVIO) for Canadian commercialization rights.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

FORUS Therapeutics product offering

Product offering

Core offering

FORUS Therapeutics commercializes two specialty prescription pharmaceutical products in Canada: BESREMI® (ropeginterferon alfa-2b), a long-acting interferon injection for adults with polycythemia vera, and XPOVIO® (selinexor), an oral XPO1 inhibitor for adults with multiple myeloma. Both drugs are in-licensed from PharmaEssentia and Karyopharm Therapeutics, and FORUS handles Canadian regulatory approvals, market access negotiations with provincial drug plans, medical affairs, and field-based sales to hematologists and oncologists.

Product overview

FORUS Therapeutics is a Canadian specialty pharmaceutical company that commercializes differentiated medicines for hematologic malignancies and cancer. The company operates with two core commercialized products: BESREMI® (ropeginterferon alfa-2b), a long-acting interferon for polycythemia vera obtained through licensing from parent company PharmaEssentia; and XPOVIO® (selinexor), an XPO1 inhibitor for multiple myeloma licensed from Karyopharm Therapeutics. Both products target rare hematologic cancers and are supported by patient assistance programs and market access initiatives across Canadian provinces.

Differentiator

Problem solved

Functional benefit

Products and services

  • BESREMI® (ropeginterferon alfa-2b) A monopegylated, long-acting interferon alfa-2b injection for the treatment of adults with polycythemia vera (PV), a rare chronic blood cancer. Administered subcutaneously once every two weeks (or every four weeks with hematological stability). Licensed from PharmaEssentia Corp.
  • XPOVIO® (selinexor) A first-in-class oral selective nuclear export (XPO1) inhibitor (SINE) in tablet form, indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Licensed from Karyopharm Therapeutics Inc.
  • ForYOU Patient Support Program (PSP) A dedicated patient support service for Canadian patients prescribed FORUS products (notably XPOVIO), assisting with reimbursement navigation, financial assistance, and treatment adherence via phone (1-833-496-8777) and fax.

Quantifiable outcome

  • XPOVIO achieved public funding across multiple provinces including Alberta, Saskatchewan, British Columbia, Ontario, Newfoundland and Labrador, New Brunswick, Nova Scotia, PEI, and Quebec
  • +2 more outcomes

Companies that use FORUS Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

FORUS Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

FORUS Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • PharmaEssentia CorporationcoreStrategic or Co-development Partner · 11 June 2026PharmaEssentia acquired FORUS Therapeutics in June 2026, making it a wholly owned subsidiary. FORUS continues to leverage its established expertise in the Canadian hematology and oncology environment while benefiting from expanded global resources and capabilities. The acquisition strengthens the combined organization's ability to support regulatory, medical, market access, and commercial activities across Canada. FORUS previously held exclusive licensing rights for BESREMI (ropeginterferon alfa-2b) for polycythemia vera in Canada.
  • Bloom Burton & Co.minorGTM or Marketing PartnerBloom Burton & Co. is a healthcare investor conference organizer. FORUS has presented at multiple Bloom Burton & Co. Healthcare Investor Conferences (2022, 2023) as part of their investor relations and corporate visibility strategy.
  • Queen’s University (PHMI Program)minorStrategic or Co-development PartnerFORUS participates in the Pharmaceutical & Healthcare Management and Innovation (PHMI) graduate program at Queen's University, hosting interns through the program as part of talent development and academic engagement.
  • Canadian MPN NetworkminorGTM or Marketing PartnerPatient advocacy organization representing myeloproliferative neoplasm (MPN) patients in Canada. Doug Chisholm (former Chair) and Patricia Saluk (current President) have publicly supported BESREMI availability in Canada.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

FORUS Therapeutics competitors and assessment

Company assessment

Direct peers

  • Paladin Labs: Canadian specialty pharmaceutical company now operating as a subsidiary of Endo, specializing in in-licensing, acquiring, and commercializing specialty products in Canada. Strong overlap in business model and Canadian commercialization expertise.
  • Verity Pharmaceuticals: Canadian specialty pharmaceutical company focused on women's health and oncology, in-licensing and commercializing products in Canada. Similar in-licensing model and Canadian-only commercial focus, with a relevant oncology overlap.
  • Cipher Pharmaceuticals: Canadian specialty pharmaceutical company based in Mississauga that acquires, in-licenses, and commercializes specialty products in Canada. Similar business model of bringing differentiated, often niche, therapies to the Canadian market through licensing partnerships.
  • Milestone Pharmaceuticals: Canadian specialty pharmaceutical company commercializing cardiovascular therapies, including an FDA-approved product. While therapeutic focus differs, the model of a Canadian-domiciled specialty pharma commercializing novel, differentiated therapies is directly comparable.
  • Knight Therapeutics: Canadian specialty pharmaceutical company headquartered in Montreal that in-licenses and commercializes innovative products in Canada and select emerging markets. Closely comparable to FORUS in business model (in-licensed assets, Canadian commercialization focus) and oncology/hematology overlap.
  • Theratechnologies: Canadian specialty biopharmaceutical company focused on oncology and HIV, commercializing in-licensed and proprietary products. Comparable commercial-stage Canadian specialty pharma with a focus on serious conditions and narrow prescriber networks.

Broad incumbents

  • Bristol Myers Squibb Canada: Canadian operations of BMS, the parent of former Celgene and a leader in multiple myeloma (Revlimid, Pomalyst, Empliciti). Competes with XPOVIO in multiple myeloma and relevant because FORUS's leadership team largely hails from Celgene Canada.
  • Bausch Health: Canadian-headquartered specialty pharmaceutical company with a broad portfolio across dermatology, gastroenterology, and neurology. Operates at significantly larger scale than FORUS but shares the Canadian commercial infrastructure and specialty pharma model.

Others

  • PharmaEssentia Corporation: Taiwan-based global biopharmaceutical company (TWSE: 6446) and FORUS's parent since June 2026; originator of BESREMI. Included as the strategic acquirer and primary licensor of FORUS's flagship asset.
  • Karyopharm Therapeutics: U.S.-based oncology company that developed XPOVIO (selinexor) and licensed Canadian commercialization rights to FORUS in 2021. Included as the originator of FORUS's other core product and a key licensor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

FORUS Therapeutics social profiles

Digital presence

FORUS Therapeutics compliance and trust

Trust signal

Compliance5 records

FORUS Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

FORUS Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

FORUS Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

FORUS Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FORUS Therapeutics

What does FORUS Therapeutics do?

FORUS Therapeutics commercializes two specialty prescription pharmaceutical products in Canada: BESREMI® (ropeginterferon alfa-2b), a long-acting interferon injection for adults with polycythemia vera, and XPOVIO® (selinexor), an oral XPO1 inhibitor for adults with multiple myeloma. Both drugs are in-licensed from PharmaEssentia and Karyopharm Therapeutics, and FORUS handles Canadian regulatory approvals, market access negotiations with provincial drug plans, medical affairs, and field-based sales to hematologists and oncologists.

Is FORUS Therapeutics a public or private company?

FORUS Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was FORUS Therapeutics founded?

FORUS Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is FORUS Therapeutics based?

FORUS Therapeutics is headquartered in Oakville, Canada, in the North America region.

How does FORUS Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing Revenue.

Who are FORUS Therapeutics's main competitors?

Direct peers on record are Paladin Labs, Verity Pharmaceuticals, Cipher Pharmaceuticals, Milestone Pharmaceuticals, Knight Therapeutics and Theratechnologies. Broad incumbents are Bristol Myers Squibb Canada and Bausch Health. Others are PharmaEssentia Corporation and Karyopharm Therapeutics.

Does FORUS Therapeutics have an API?

No public API is recorded for FORUS Therapeutics.

What industry is FORUS Therapeutics in?

FORUS Therapeutics's product category is Specialty Pharmaceuticals - Oncology/Hematology. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FocustaiwanTaiwan drugmaker PharmaEssentia plans US$46 million Puerto Rico plant as it expands global reach - Focus TaiwanTaiwan drugmaker PharmaEssentia plans a US$46 million production facility in Puerto Rico to begin operations in 2027, supporting its blood cancer drug Ropeg. The company also acquired Canadian firm FORUS Therapeutics for US$36.5 million. Ropeg has been approved for essential thrombocythemia and polycythemia vera in multiple countries.EIN PresswireTaiwan drugmaker PharmaEssentia plans US$46 million Puerto Rico plant as it expands global reach - Focus TaiwanTaiwan's PharmaEssentia plans a US$46 million production facility in Puerto Rico to begin operations in 2027, supporting its blood cancer drug Ropeg. The company also acquired Canadian firm FORUS Therapeutics for US$36.5 million. Ropeg has been approved for essential thrombocythemia and polycythemia vera in multiple countries.BioSpacePharmaEssentia Announces Health Canada Approval of BESREMi® (ropeginterferon alfa-2b) for Polycythemia Vera (PV)PharmaEssentia's subsidiary FORUS Therapeutics received a Notice of Compliance from Health Canada for BESREMi (ropeginterferon alfa-2b) to treat adults with polycythemia vera. The drug is expected to become commercially available in Canada in the coming weeks. The company has already secured approval in over 40 countries.ForustherapeuticsFORUS Therapeutics Joins PharmaEssentia to Strengthen Focus on Hematology and Oncology in CanadaFORUS Therapeutics was acquired by PharmaEssentia, a global biopharmaceutical company, to strengthen its focus on hematology and oncology in Canada. The deal builds on their existing partnership for ropeginterferon alfa-2b, an investigational treatment for polycythemia vera under review by Health Canada. FORUS will continue its work with healthcare professionals and partners.YahooPharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in CanadaPharmaEssentia entered an exclusive licensing agreement with FORUS Therapeutics to commercialize BESREMi for polycythemia vera in Canada. The deal includes milestone payments of up to $107 million, with FORUS overseeing registration and commercialization. The company plans to expand to other myeloproliferative neoplasms indications.Business Wire BlogPharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in CanadaPharmaEssentia entered an exclusive licensing agreement with FORUS Therapeutics to commercialize BESREMi for polycythemia vera in Canada. The deal includes milestone payments of up to $107 million, with FORUS to handle registration and commercialization. The product is already approved in over 40 countries.PR NewswireKaryopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial UpdateKaryopharm Therapeutics announced preliminary Q4 2020 total revenues of $35-36 million and full year 2020 revenues of $108-109 million, with XPOVIO net product sales of $20-20.5 million for Q4. The company reported a 4-6% sales decline from Q3 due to the U.S. COVID-19 surge and increased competition in the penta-refractory multiple myeloma setting, though prescription demand improved in December following FDA approval for an expanded multiple myeloma indication on December 18, 2020. Karyopharm also entered an exclusive distribution agreement with FORUS Therapeutics for Canada and its partner Antengene filed for regulatory approval of selinexor in Australia, Singapore, and South Korea.